INDIANAPOLIS — Drug maker Eli Lilly will present data from more than 30 studies at the American Society of Clinical Oncology’s annual meeting in Chicago next month, the company said Monday.
Studies will include “PARAMOUNT,” a late-stage clinical trial investigating the drug Alimta (pemetrexed) in patients with advanced non-squamous non-small cell lung cancer, as well as studies on Gemzar (gemcitabine) and Erbitux (cetuximab) with partner companies Bristol-Myers Squibb and Merck KGaA.